Medical Journal News

As paediatricians working in the US, we view the changes being made to our healthcare and education systems, research enterprise, and regulatory agencies1 as truly dystopian.The damage is clear to us. The breakdown of information from the Centers for Disease Control and Prevention; unjustified firing of workers from the National Science Foundation, US Department of Agriculture, Food and Drug Administration, and Environmental Protection Agency; decreasing the funding of university research through the National Institutes of Health; dismantling the US Agency for International Development; and withdrawal from the World Health Organization and the Paris Climate Agreement have disproportionately adverse effects on children. Children will suffer from diseases and disabilities that otherwise could be prevented and treated, a dire consequence of policies adopted by the very federal government entrusted with promoting and protecting their health, development, and functioning.Dictators have historically used health as a target to destroy the core strength of their...

In this episode of Sharp Scratch, the panel got together to discuss the importance of properly listening to patients.The panel was joined by guest Rageshri Dhairyawan to explore how medical students and doctors can work to improve their listening by increasing their awareness of biases that may lead to some groups of patients being dismissed. The episode highlighted the broader implications of not properly hearing patients, including the impact on health equity. The discussion also covered the challenges of dealing with uncertainty and acknowledging the social factors that can affect healthcare outcomes. The episode emphasised the ways in which becoming a better listener as a medical professional can help us to provide more compassionate and holistic care.Rageshri Dhairyawan is a consultant in sexual health and HIV medicine at Barts Health NHS Trust and deputy director of the SHARE Collaborative for Health Equity, Queen Mary University of London. She is author...

New England Journal of Medicine, Volume 392, Issue 12, Page 1237-1240, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1203-1214, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1246-1248, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1245-1246, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1243-1245, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1241-1242, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1232-1233, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1230-1232, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1215-1215, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1216-1227, March 27, 2025.

New England Journal of Medicine, Volume 392, Issue 12, Page 1234-1236, March 27, 2025.

New England Journal of Medicine, Ahead of Print.

Rising cases of tuberculosis (TB) and measles and an intense influenza and respiratory syncytial virus (RSV) season were seen in England in 2024-25, reiterating the fact that “we cannot be complacent,” the outgoing head of the UK Health Security Agency (UKHSA) has said.The agency’s first report on infectious diseases looks at data from 2023 to early 2025 and acknowledges that social mixing, international travel, migration, and vaccine hesitancy following the covid-19 pandemic have contributed to these patterns of infection.1Provisional data for 2024 show that there were 600 new cases of TB in England in 2024, 13% more than in 2023. This followed an 11% increase in cases in 2023, with 4855 notifications of the disease compared with 4380 in 2022.If cases of TB continue to increase on their current trajectory the UK would lose its World Health Organisation low incidence status, warned Jenny Harries, chief executive of the UKHSA, at...

Decades of progress in improving childhood survival are being put at risk because of major cuts to aid funding, the United Nations has warned.In a report1 published on 25 March the UN found that the number of children dying globally before their 5th birthday has more than halved from 10.1m in 2000 to 4.8m in 2023. Stillbirths have declined modestly, from 2.9m in 2000 to 1.9m in 2021.2But it warned that these gains are now under threat as major aid donors such as the US have announced funding cuts. Earlier this month the Trump administration permanently cancelled funding for nearly 10 000 projects supporting global health and development, equating to a cut of nearly $60bn in aid spending.3 US cuts to foreign aid have already closed vital child malnutrition services in war torn Sudan.4World Health Organization director general Tedros Adhanom Ghebreyesus said, “In the face of global funding cuts, there...

The chancellor of the exchequer, Rachel Reeves, will set out the UK government’s spending plans in her spring statement on 26 March.1 The consultative green paper, Pathways to Work,2 has already outlined plans to cut several billion from the welfare budget, with the aim of saving £5bn by 2029-30.3 The plans include stricter criteria for personal independence payments (PIP) for people with disabilities; halving incapacity benefit payments under Universal Credit for new claimants; and restriction of incapacity benefit top-ups to those aged 23 years and older.Ministers have argued there is a “moral case” for these cuts, and that “people that can work [should be] able to work.”3 However, the chancellor’s approach is unlikely to achieve this goal for two key reasons. First, high rates of economic inactivity in the UK reflect its almost unique failure among industrialised countries to recover population health after the pandemic,456 which came on top of...

In the UK more than 3 in every 1000 people are taking glucagon-like peptide-1 (GLP-1) agonist drugs, says Kevin McCarroll, consultant physician and geriatrician at St James Hospital, Dublin.1 Depending on the region, 77-179 in 100 000 people are using the leading GLP-1 drug semaglutide (Ozempic for type 2 diabetes, Wegovy for obesity), he says.1 And these are just the official prescribing figures—anecdotal evidence suggests many are purchasing the drugs from unofficial sources.Growing evidence of the drugs’ efficacy for weight loss2 is fuelling demand worldwide. The number of patients in the US approved for GLP-1 agonist treatment for obesity rose from 190 000 a month in 2021 to 1.8 million in 2024.3 Analysis of the US market shows that 5.2% of women and 4.2% of men with obesity are being prescribed the drugs, although access varies.“The global supply shortage seen in 2024 was at least partly because of a surge...

by Hiroki Shinmura, Youhei Tsunoda, Takashi Matsushima, Ryuhei Kurashina, Asako Watanabe, Eika Harigane, Nozomi Ouchi, Shunji Suzuki

Background

In Japan, the lateral position method is known as a postural therapy for breech presentation wherein the mother lies down in lateral position according to the orientation of the fetal back. Few studies have formally tested lateral position management for breech presentation, and no method exists to prevent breech recurrence after cephalic version. We hypothesized that postural management comprising a combination of opposite-side lateral position for breech presentation and same-side lateral position after cephalic version demonstrates a clinically relevant effect size on breech presentation.

Methods and findings

We conducted a stratified, open-label randomized controlled trial at an academic hospital in Kawasaki, Japan. A total of 200 women diagnosed with breech presentation between 28 +  0 and 30 +  0 gestational weeks were randomized to postural management (n =  100) or control (no intervention, n =  100) group. The intervention was instruction every 2 weeks on lying in the lateral position on the opposite-side of fetal back for breech presentation and on the same-side of fetal back for head-first presentation. The primary outcome was the rate of fetuses in breech presentation at 37 weeks of gestation, and the secondary outcomes were cesarean delivery, cesarean delivery for breech presentation, head presentation 2, 4, and 6 weeks later, breech presentation recurrence, and adverse events. Breech presentation rate at 37 gestational weeks was 11% in the intervention group, using the combination of the opposite-side and same-side lateral positions, compared with 19% in the control group. However, we found no statistical significance in the intention-to-treat analysis (11% [11/100] versus 19% [19/100]; relative risk, 0.58 [95% CI, 0.29 to 1.15]; p =  0.11). In the control group, 23 participants (23%) unknowingly took the same posture as the intervention group, and the prespecified per-protocol analysis excluding crossover found the same direction of effect but with statistical significance. In the intention-to-treat analysis, the intervention group had a higher cephalic version rate 2 weeks after the instruction (69% [69/100] versus 54% [54/100]; relative risk, 0.67 [95% CI, 0.47 to 0.96]; p =  0.029), and lower breech presentation recurrence rates (2% [2/91] versus 10% [9/88]; relative risk, 0.22 [95% CI, 0.048 to 0.97]; p =  0.031) than the control group. Regarding adverse events in the intervention group, three participants experienced discomfort and one participant complained of pain in the lateral abdomen; these symptoms resolved spontaneously.

Conclusions

For breech presentation at the beginning of the third trimester, providing postural therapy instruction on opposite-side lateral positioning and same-side lateral positioning was associated with 8% reduction of breech fetuses at 37 gestational weeks compared with the control group, but this primary endpoint did not reach statistical significance. Regarding the secondary endpoints, the intervention group showed a significantly higher rate of cephalic version after 2 weeks and lower rate of breech recurrence. The direction of the effect of postural therapy based on fetal back position on breech presentation was promising, and further research to validate this approach, with consideration for unplanned participant crossover, may be warranted.

Trial registration

UMIN Clinical Trials Registry (UMIN000043613, https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049800).

Medical students from across the UK rallied outside the Department for Education on 19 March to demand adequate financial support.BMA representatives from the Medical Students Committee delivered a letter to Bridget Phillipson, the secretary of state for education, asking the government to “ensure that both undergraduate and graduate students are eligible for the full Student Finance England maintenance loan provision for all years of study,” as well as improving access to funding through the NHS bursary, “including improving the claims process and exploring new sources of funding.”Medical students stop being solely funded by Student Finance England in their fifth year when maintenance loans fall from a maximum of £10 277 to £2670 an academic year. This is then topped up with the NHS bursary of £1020 and a means tested grant of up to £2696 for those outside of London and £3255 for those in London. An additional £86 a...